Company: CDT
Filing Date: 2025-07-31
Form Type: S-3
Source: 0001641172-25-021729
Chunk: 9

Company: CDT Equity Inc.
Filing Date: 2025-07-31
Form: S-3
Chunk 9
---
 of the Company related to cryptocurrency. Such strategies include the potential adoption of a cryptocurrency treasury reserve strategy. For services rendered, the Company has agreed to compensate Harold Eytan 95,618 shares to satisfy the $240,000 fee due to Harold Eytan pursuant to the Consulting Agreement. Harold Eytan is not a related party to the Company.

E3 Fund SP

On May 20, 2025, the Company issued 4,868 Shares to E3 Fund SP, in connection with services provided in March 2025 regarding the negotiation and resolution of previously issued indebtedness (the “E3 Issuance”).

Corporate Information

On September 22, 2023, a merger transaction (the “Business Combination”) between Conduit Pharmaceuticals Limited (“Old Conduit”), Murphy Canyon Acquisition Corp (“MURF”) and Conduit Merger Sub, Inc., a Cayman Islands exempted company and a wholly owned subsidiary of MURF (“Merger Sub”), was completed pursuant to the Agreement and Plan of Merger, dated November 8, 2022, as amended, (the “Merger Agreement”). Pursuant to the terms of the Merger Agreement, at the closing, (i) Merger Sub merged with and into Old Conduit, with Old Conduit surviving the Business Combination as a wholly-owned subsidiary of MURF, and (ii) MURF changed its name from Murphy Canyon Acquisition Corp. to Conduit Pharmaceuticals Inc.

Our principal executive offices are located at 4581 Tamiami Trail North, Suite 200, Naples, Florida 34103, and our telephone number is (646) 491-9132. Our website address is http://www.conduitpharma.com. The information contained on or otherwise accessible through our website is not part of this prospectus.

| 4 |

<div align='center'>The Offering</div>

| Shares                                            
 of Common                                         
 Stock offered by the                              
 Selling Stockholders                              |     | 255,285                                                                                                                                  
 shares of Common Stock issued pursuant to the Joint Development Agreement, the Consulting Agreement, and the E3 Issuance.                |
| Use                                               
 of proceeds                                       |     | We                                                                                                                                       
 are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of the shares of Common      
 Stock covered hereby by the Selling Stockholders. See “Use of Proceeds.”                                                                 |
| Terms                                             
 of this offering; Determination of offering price |     | The